3billion's stock price is strong in the early trading on the 17th. The buying pressure is interpreted as a result of 3billion signing a memorandum of understanding (MOU) for genetic testing cooperation with AstraZeneca.
3billion is trading at 6,170 won, up 500 won (8.82%) from the previous trading day as of 9:35 a.m. on the KOSDAQ market.
The artificial intelligence (AI)-based rare genetic disease diagnostic corporation 3billion announced that it signed an MOU with Korea AstraZeneca before the market opened on the swift diagnosis of patients with atypical hemolytic uremic syndrome (aHUS), one of the rare diseases.
For aHUS patients, the rapid deterioration of their condition after onset makes it extremely important to diagnose within the golden time, but existing genetic tests have taken about 4 to 6 weeks. Through this collaboration, 3billion and AstraZeneca plan to establish a genetic testing system that can complete the diagnosis of aHUS patients within 2 weeks, ensuring that patients do not miss the golden time for treatment.
Keum Chang-won, representative of 3billion, noted, "Interpreting the pathogenicity of millions of genetic variants rapidly is difficult without the help of artificial intelligence (AI)," adding, "We will provide more rapid and accurate genetic testing for aHUS patients using the AI genetic diagnostic system."